Abstracts tagged "TNF-blocking Antibody"

Abstract Number: 1772 • ACR Convergence 2020
Vaccinations of Infants Born to Mothers on TNF Inhibitors: Safe Administration of Live-vaccines Given Per the National Immunization Program
Eman Satti¹, Nawal Hadwan¹ and Samar Al Emadi¹, ¹Hamad medical corporation, DOHA, Qatar
Background/Purpose: Biologic Disease-Modifying agents (bDMARDs) including TNF inhibitors are increasingly used during pregnancy over the last few decades for a variety of autoimmune conditions. Nevertheless,…
Abstract Number: 2029 • ACR Convergence 2020
Therapeutic Drug Monitoring Compared to Standard Treatment of Patients Starting Infliximab: Results from a Multicenter Randomized Controlled Trial of 400 Patients
Silje Syversen¹, Guro Goll¹, Kristin Jørgensen², Øystein Sandanger³, Joseph Sexton¹, Inge C. Olsen³, Johanna Gehin³, Marthe Brun¹, Cato Mørk⁴, Tore K. Kvien¹, Jørgen Jahnsen⁵, Nils Bolstad³ and Espen Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus Dermatology Center, Lørenskog, Norway, ⁵Akershus University Hospital, Lørenskog, Norway
Background/Purpose: A lack or loss of response to TNFα inhibitors (TNFi) has been associated with low serum drug levels and formation of anti-drug antibodies (ADAb).…
Abstract Number: 0168 • ACR Convergence 2020
Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice
Uwe Pleyer¹, Salem Almutairi², Conor Murphy³, Rola Hamam⁴, Karina Julian⁵, Shereen Hammad⁶, Orsolya Nagy⁷, Zohar Habot-Wilner⁸, Zsuzsanna Szepessy⁹, Yan Guex-Crosier¹⁰ and Sofia Androudi¹¹, ¹Charité Universitätsmedizin Berlin, Klinik für Augenheilkunde, Berlin, Germany, ²Al-Bahar Ophthalmology Center - Al-Sabah Hospital, Kuwait City, Kuwait, ³Royal Victoria Eye & Ear Hospital, Dublin, Ireland, ⁴American University of Beirut, Beirut, Lebanon, ⁵Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁶AbbVie Biopharmaceuticals GmbH, Dubai, United Arab Emirates, ⁷AbbVie Kft, Budapest, Hungary, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Semmelweis University, Budapest, Hungary, ¹⁰Jules-Gonin Eye Hospital, Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland, ¹¹University of Thessaly, Larissa, Greece
Background/Purpose: VISUAL clinical trials demonstrated efficacy and safety of adalimumab (ADA) in patients with active and inactive non-infectious, intermediate, posterior, or panuveitis (NIIPPU).1-3 The purpose…
Abstract Number: 0719 • ACR Convergence 2020
Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study
Edoardo Marrani¹, Hendrik Rusche², Francesco Terzani³, Elisa Peroni⁴, Feliciana Real-Fernandez⁵, Olivier Monasson⁴, Roberta Ponti⁶, Gabriele Simonini⁷, Anna Maria Papini³ and Paolo Rovero⁵, ¹University of Florence, Firenze, Italy, ²Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, Cergy-Pontoise,, France, ³PeptLab, Dep. Chemistry, University of Florence, Sesto FIorentino, Italy, ⁴Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, cergy-pontoise, France, ⁵PeptLab, Dep. NEUROFARBA, University of Florence, Firenze, Italy, ⁶Pediatric Department, University of Udine, udine, Italy, ⁷Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy
Background/Purpose: Immunogenicity and development of anti-drug antibodies have been associated with treatment failure and adverse events during biologic treatment. Anti-drug antibodies (ADAs) have been reported…
Abstract Number: 0722 • ACR Convergence 2020
Evaluation of Flare Rate and Tapering Strategies in Juvenile Idiopathic Arthritis
Antía García-Fernández¹, Andrea Briones-Figueroa¹, Laura Calvo-Sanz¹, África Andreu Suárez¹ and Alina Lucica Boteanu², ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Biological treatment (BT) has changed the perspectives of Juvenile Idiopathic Arthritis (JIA) patients, but it remains unclear when and how to taper or to withdraw…
Abstract Number: 0804 • ACR Convergence 2020
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
Elise van Mulligen¹, Saad Ahmed¹, Angelique Weel², Mieke Hazes³, Annette van der Helm - van Mil⁴ and Pascal de Jong¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…
Abstract Number: 1223 • ACR Convergence 2020
Characterizing Rheumatoid Arthritis Patients by Their Biologic DMARD Prescription History
Piyam Das¹, Sicong Huang², Kumar Dahal², Huahua Zheng³, Jonathan Coblyn², Michael Weinblatt², Tianxi Cai¹ and Katherine Liao², ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA
Background/Purpose: IIn rheumatoid arthritis (RA), a patient’s biologic disease modifying anti-rheumatic drug (bDMARD) history and the duration of time they remain on each drug may…
Abstract Number: 1227 • ACR Convergence 2020
Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors
Borja Hernandez-Breijo¹, Chamaida Plasencia², Victoria Navarro-Compán³, Israel Nieto-Gañán⁴, Cristina Sobrino⁵, Ana Martínez-Feito⁶, Carlota García-Hoz⁴, Paloma Lapuente-Suanzes⁴, Javier Bachiller-Corral⁷, Gema Bonilla², Cristina Pijoán-Moratalla⁷, Garbiñe Roy⁴, Mónica Vázquez⁷, Alejandro Balsa², Luisa M Villar⁴, Dora Pascual-Salcedo⁸ and Eulalia Rodríguez-Martín⁴, ¹Immuno-rheumatology Research group. IdiPAZ. La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ³Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁴Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, ⁵Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, ⁶Hospital Unversitario La Paz- idipaz, Madrid, Spain, ⁷Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario La Paz- Idipaz, Madrid, Spain
Background/Purpose: Biological therapies, as TNF inhibitors (TNFi) are increasing remission rates in rheumatoid arthritis (RA) patients although these are still limited. This study aims to…
Abstract Number: 1346 • ACR Convergence 2020
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis
Runsheng Wang¹, Abhijit Dasgupta² and Michael Ward³, ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²NIAMS, Bethesda, ³National Institutes of Health, Bethesda, MD
Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous. In clinical practice, both patients and…
Abstract Number: 1403 • ACR Convergence 2020
Differential Effect of Abatacept vs TNF Blockers, on the Frequency of Circulating Follicular Helper (Tfh) and Periperal Helper (Tph) T Cells in Rheumatoid Arthritis
María-José Santos-Bornez¹, Paula Fortea-Gordo¹, Laura Nuño¹, Alejandro Villalba¹, Diana Peiteado¹, Irene Monjo², Alejandro Balsa³ and Maria-Eugenia Miranda-Carus¹, ¹Hospital La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital- IdiPAZ, Madrid, Spain, ³Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain
Background/Purpose: CXCR5+PD-1hi follicular helper (Tfh) and CXCR5-PD-1hi peripheral helper (Tph) T cells play an important role in the pathogenesis of Rheumatoid Arthritis (RA) by providing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].